GlaxoSmithKline sales contract by 1.0 per cent in 2012

FTSE-100 listed pharmaceutical giant GlaxoSmithKline (GSK) has posted a 1.0 per cent decline in its annual turnover for the year ending December 31st, according to a financial update issued by the company on Wednesday.

FTSE-100 listed pharmaceutical giant GlaxoSmithKline (GSK) has posted a 1.0 per cent decline in its annual turnover for the year ending December 31st, according to a financial update issued by the company on Wednesday.

Turnover contracted to £26,431m with the adverse impact to performance in 2012 being blamed on weaker than expected sales from GSK's European business.

European sales lower than expectedGroup turnover by geographic region contracted 7.0% to £7,320m at constant exchange rates, while sales slid 4.0% to £8,446m in the US.

In Japan, GSK's sales also dropped by 5.0% to £2,225m. These reductions in sales were partially offset by growth in the Emerging Markets region.

Emerging markets potentialGSK reported that total sales in emerging markets currently account for 26% of its business and the group reported sales there had risen by 10% over the year.

The group delivered core earnings per share of 112.7p in 2012 and cash inflow from operating activities of £7.0bn before legal settlements.

Pharmaceuticals turnover fell 2.0%, which GSK said reflected increased pressure from austerity measures in Europe.

Vaccines turnover declined 2.0%, reflecting the impact of lower sales of Cervarix in Japan - £132m worth of Cervarix was sold in 2012, compared to £344m in 2011 following the completion of the 2011 HPV vaccination catch-up programme.

R&D: 15 products potentilly launchable in coming three yearsGSK reported that "significant progress" had been made in its research and development department, stating that the group had six new products under regulatory review. It said that over the next 15 years, GSK would have the potential to launch around 15 new products globally.

Analysts' predictions: Turnover beats expectationsOverall, GSK's results exceeded the expectations of analysts at Credit Suisse.

Analysts at Credit Suisse forecast in January that GlaxoSmithKline would report £26,358m in group sales - slightly less than the £26,431m which was reported on Wednesday.

The financial services company had also forecast a core earnings per share value not diluted at 111.7p. GSK's results showed a core earnings per share of 112.7p.

GSK's share price was down 0.21% to 1,439.50p at 13:08 on Wednesday afternoon.

MF

Recommended

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework
Investment strategy

The MoneyWeek Podcast: picking stocks is fun, but you need to do your homework

John Stepek talks to Steve Clapham, investor, analyst and author of The Smart Money Method, about the dangers in picking individual stocks and why you…
8 Apr 2021
BP looks set to return more money to shareholders as it beats expectations
Energy stocks

BP looks set to return more money to shareholders as it beats expectations

Oil major BP is to embark on a share buyback programme after significantly reducing its debts. Saloni Sardana looks at what it means for your portfoli…
6 Apr 2021
Deliveroo has hit the market – but it’s not getting the warmest welcome
UK stockmarkets

Deliveroo has hit the market – but it’s not getting the warmest welcome

Food delivery company Deliveroo made its debut on the stockmarket this morning. But with the share price sliding by 30% straight away, it’s not made t…
31 Mar 2021
Three stocks to buy now that will come back stronger after Covid-19
Share tips

Three stocks to buy now that will come back stronger after Covid-19

Professional investor Ed Wielechowski of Odyssean Capital, chooses three compelling stocks that should thrive in a post-pandemic world.
29 Mar 2021

Most Popular

“Joke” cryptocurrency dogecoin goes to the moon. What’s going on?
Bitcoin

“Joke” cryptocurrency dogecoin goes to the moon. What’s going on?

Dogecoin – a cryptocurrency created as a joke – has risen by more than 9,000% this year alone. Saloni Sardana looks at how something that began as an …
19 Apr 2021
The FTSE 100 has clawed back above 7,000 – how much higher can it go?
UK stockmarkets

The FTSE 100 has clawed back above 7,000 – how much higher can it go?

The FTSE 100 index has risen to over 7,000 for the first time in over a year – it now sits just above where it was in 1999. But its era of neglect cou…
19 Apr 2021
The bitcoin bubble will burst: here’s how to play it
Bitcoin

The bitcoin bubble will burst: here’s how to play it

The cryptocurrency’s price has soared far beyond its fundamentals, says Matthew Partridge. Here, he looks at how to short bitcoin.
12 Apr 2021